Other
CABG
0
Pipeline Programs↗
4
Active Trials↗
1
Companies Involved↗
CABG is an early-stage landscape with 0 programs across 1 company. The most active players are AstraZeneca.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
No pipeline programs currently tracked for this disease.
Analysis
Trial Status
13
clinical trials
Unknown status4 · 31%
Completed4 · 31%
Recruiting4 · 31%
Terminated1 · 8%
Clinical Trials
Trial Activity
13 trials
Study of Sivelestat Sodium in OPCABG
Recruiting·—·Phase 2·NCT07118930·62 enrolled
SAPT Versus DAPT in Incomplete Revascularization After CABG
Recruiting·—·Phase 3·NCT03789916·800 enrolled
Histidine-Tryptophan-Ketoglutarate Solution Versus Blood Cardioplegia in CABG
Completed·—·Phase 1·NCT04203680·320 enrolled
Feasibility Study of BMAC Enhanced CABG
Terminated·—·Phase 1/2·NCT01074099·5 enrolled
Comparison Between Levosimendan and Adrenaline in CABG Patients
Unknown status·—·N/A·NCT05222256·52 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)